Literature DB >> 18354383

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.

G L Bakris1, R D Toto, P A McCullough, R Rocha, D Purkayastha, P Davis.   

Abstract

Clinical practice guidelines recommend blockers of the renin-angiotensin system alone or in combination with other agents to reduce blood pressure and albuminuria in patients with type 2 diabetes. Dihydropyridine calcium channel blockers, however, may lower blood pressure but not albuminuria in these patients. Here we tested the hypothesis that combining an ACE inhibitor with either a thiazide diuretic or a calcium channel blocker will cause similar reductions in blood pressure and albuminuria in hypertensive type 2 diabetics. We conducted a double blind randomized controlled trial on 332 hypertensive, albuminuric type 2 diabetic patients treated with benazepril with either amlodipine or hydrochlorothiazide for 1 year. The trial employed a non-inferiority design. Both combinations significantly reduced the urinary albumin to creatinine ratio and sitting blood pressure of the entire cohort. The percentage of patients progressing to overt proteinuria was similar for both groups. When we examined patients who had only microalbuminuria and hypertension we found that a larger percentage of the diuretic and ACE inhibitor normalized their albuminuria. We conclude that initial treatment using benzaepril with a diuretic resulted in a greater reduction in albuminuria compared to the group of ACE inhibitor and calcium channel blocker. In contrast, blood pressure reduction, particularly the diastolic component, favored the combination with amilodipine. The dissociation between reductions in blood pressure and albuminuria may be related to factors other than blood pressure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354383     DOI: 10.1038/ki.2008.102

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  48 in total

Review 1.  Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Authors:  Emaad M Abdel-Rahman; Lawand Saadulla; W Brian Reeves; Alaa S Awad
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

2.  Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension.

Authors:  L Gabriel Navar
Journal:  J Appl Physiol (1985)       Date:  2010-12

3.  Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection.

Authors:  Masanori Abe; Masayoshi Soma
Journal:  Hypertens Res       Date:  2015-10-01       Impact factor: 3.872

Review 4.  Thiazide effects and adverse effects: insights from molecular genetics.

Authors:  David H Ellison; Johannes Loffing
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

5.  Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan.

Authors:  S Wang; J Li; X Zhou; K Liu; X Zhang; Q Meng; R Shi; D Shi; X Chen
Journal:  J Hum Hypertens       Date:  2017-07-13       Impact factor: 3.012

6.  Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.

Authors:  Natanong Thamcharoen; Paweena Susantitaphong; Supakanya Wongrakpanich; Pakawat Chongsathidkiet; Pakpoom Tantrachoti; Siwadon Pitukweerakul; Yingyos Avihingsanon; Kearkiat Praditpornsilpa; Bertrand L Jaber; Somchai Eiam-Ong
Journal:  Hypertens Res       Date:  2015-07-02       Impact factor: 3.872

Review 7.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

8.  Albuminuria-reducing effect of angiotensin II receptor blocker plus hydrochlorothiazide combination therapy in renal transplant recipients.

Authors:  Toshihide Naganuma; Yoshiaki Takemoto; Junji Uchida; Taiyou Ootoshi; Nobuyuki Kuwabara; Satoshi Maeda; Tatsuya Nakatani
Journal:  Exp Ther Med       Date:  2012-04-11       Impact factor: 2.447

9.  Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.

Authors:  Jean-Marie Krzesinski; Eric P Cohen
Journal:  Core Evid       Date:  2010-06-15

Review 10.  Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.

Authors:  Thomas Mengden; Sakir Uen; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.